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Objectives N The National Health Service (NHS) in the UK is faced with increasing cost pressures that make the efficient use of resources paramount.
N Both the National Institute for Health and Care Excellence (NICE) and the British Society of Gastroenterology (BSG) guidelines state that patients with irritable bowel syndrome (IBS) should be managed in the primary care setting. 1, 2 Despite this, up to 50%
of patients with a diagnosis of IBS are referred to secondary care for further investigations. 3 Reasons for referral include diagnostic uncertainty and/or advice on the further management of symptoms.
N Recent published evidence has shown that the diagnosis of IBS-C in primary care is rarely changed following investigation in secondary care. 4 N Also, outpatient visits and lower gastrointestinal (GI) endoscopic investigations consume considerable NHS resource.
N This study aimed to estimate admission costs and primary care prescribing costs associated with the treatment of IBS in England.
Methods

Databases analysed
N AXON is a health data warehouse that provides interrogative analysis and health intelligence on Hospital Episode Statistics (HES).
The Health and Social Care Information Centre (HSCIC) provided these data via a commercial licence.
N Prescription Analysis and Cost Tabulation (PACT) is a national
data set published by the HSCIC that analyses primary care prescribing data in terms of cost and number of items (volume). (Table 3) .
Data collection and synthesis
N In addition, 28,849 patients were recorded with IBS-related symptom codes at a cost of £11,002,874 (Table 3) .
N The total tariff cost of outpatients coded with IBS or related symptoms was £11,815,209 (Table 3) .
Hospital admissions and tariff costs
N During 2012/2013 the total number of patients admitted to gastroenterology and colorectal surgery specialities was 116,307 at a total cost of £95,692,068.
N Overall, 918 patients were coded (in the primary diagnostic position) as having IBS with diarrhoea and 2599 as having IBS without diarrhoea, at tariff costs of £824,897 and £1,959,408, respectively (Table 4) .
N In addition, 112,790 patients were coded (in the primary diagnostic position) with IBS-related symptoms, at a tariff cost of £92,907,764 (Table 4) . 
Disclosures
Mark Rance is an employee of Almirall UK. 
